BLU-945 manufacturers
- BLU-945
-
- $97.00 / 1mg
-
2024-11-19
- CAS:2660250-10-0
- Min. Order:
- Purity: 99.16%
- Supply Ability: 10g
|
| | BLU-945 Basic information |
| Product Name: | BLU-945 | | Synonyms: | BLU-945;N-[2-[(3S,4R)-3-Fluoro-4-methoxy-1-piperidyl]-4-pyrimidinyl]-5-isopropyl-8-[(2R,3S)-2-methyl-3-[(methylsulfonyl)methyl]-1-azetidinyl]isoquinolin-3-amine;N-[2-[(3S,4R)-3-fluoro-4-methoxy-1-piperidyl]pyrimidin-4-yl]-5-isopropyl-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]isoquinolin-3-amine;3-Isoquinolinamine, N-[2-[(3S,4R)-3-fluoro-4-methoxy-1-piperidinyl]-4-pyrimidinyl]-5-(1-methylethyl)-8-[(2R,3S)-2-methyl-3-[(methylsulfonyl)methyl]-1-azetidinyl]-;N-(2-((3S,4R)-3-Fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-yl)-5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-3-amine;N-{2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl}-8-[(2R,3S)-3-(methanesulfonylmethyl)-2-methylazetidin-1-yl]-5-(propan-2-yl)isoquinolin-3-amine | | CAS: | 2660250-10-0 | | MF: | C28H37FN6O3S | | MW: | 556.7 | | EINECS: | | | Product Categories: | blu945 | | Mol File: | 2660250-10-0.mol |  |
| | BLU-945 Chemical Properties |
| Boiling point | 784.6±70.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 7.87±0.10(Predicted) | | color | Light yellow to yellow | | InChIKey | LIMFPAAAIVQRRD-MCEZSBKONA-N | | SMILES | C(C1=CC=C(N2C[C@H](CS(=O)(=O)C)[C@H]2C)C2C=NC(NC3C=CN=C(N4CC[C@@H](OC)[C@@H](F)C4)N=3)=CC1=2)(C)C |&1:7,13,28,31,r| |
| | BLU-945 Usage And Synthesis |
| Description | BLU-945 is a potent, highly selective, reversible, and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. BLU-945 can be used for research on lung cancer, including non-small cell lung cancer (NSCLC)[1]. | | Chemical Properties | IUPAC/Chemical Name: N-(2-((3S,4R)-3-fluoro-4-methoxypiperidin-1-yl)pyrimidin-4-yl)-5-isopropyl-8-((2R,3S)-2-methyl-3-((methylsulfonyl)methyl)azetidin-1-yl)isoquinolin-3-amine. | | Side effects | According to clinical studies of BLU-945, common side effects of BLU-945 monotherapy include: rash, diarrhoea, nausea, vomiting, headache, dry skin, onychomycosis, and elevated alanine aminotransferase and aspartate aminotransferase.
Common side effects of the combination of BLU-945 and ositinib include: headache, nausea, fatigue, decreased appetite, vomiting, diarrhoea, dry skin, acne-like dermatitis and onychomycosis. | | in vitro | BLU-945 has inhibitory activity against the EGFRm/T790M double and EGFRm/T790M/C797Striple mutants with IC50 value range from 1.2-4.4 nM.
BLU-945 (0- 10 mM, 4 h) inhibit EGFR phosphorylation in the EGFR L858R/T790M/C797S, and EGFR ex19del/T790M/C797S mutant cell lines. | | References | [1] Y. Elamin. “BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study.” Journal of Clinical Oncology (2023).
|
| | BLU-945 Preparation Products And Raw materials |
|